Shared on 23 Aug 25
Fair value Increased 9.17%Despite a lower revenue growth forecast, analysts have raised Implenia's price target, likely reflecting improved net profit margin expectations, with fair value increasing from CHF57.25 to CHF61.50. What's in the News Implenia secured new building construction contracts worth approximately CHF 400 million, including a medical research and training center in Bern and a residential project in Zurich Oberland, with both projects emphasizing specialized expertise and sustainable standards.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 4.65%AnalystConsensusTarget has increased revenue growth from 1.7% to 2.0%.
Shared on 02 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 4.05%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 13 Mar 25
Fair value Decreased 18%AnalystConsensusTarget has increased revenue growth from 0.9% to 1.6%, increased profit margin from 2.3% to 3.0% and decreased future PE multiple from 10.1x to 8.1x.